101,239 Shares in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. acquired a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 101,239 shares of the company's stock, valued at approximately $1,225,000. SBI Securities Co. Ltd. owned about 0.11% of Gyre Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC purchased a new position in Gyre Therapeutics in the third quarter worth approximately $47,000. Barclays PLC raised its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after acquiring an additional 6,855 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after purchasing an additional 1,389 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics during the third quarter worth approximately $334,000. Finally, State Street Corp boosted its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock valued at $1,310,000 after buying an additional 8,412 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company's stock.

Insider Buying and Selling

In related news, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 30,054 shares of company stock worth $342,277 in the last quarter. 19.52% of the stock is owned by insiders.

Remove Ads

Gyre Therapeutics Price Performance

NASDAQ:GYRE traded down $0.38 during midday trading on Friday, hitting $10.32. 232,156 shares of the company were exchanged, compared to its average volume of 81,399. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $20.09. The company has a fifty day simple moving average of $11.35 and a 200 day simple moving average of $12.35.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.